SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, presented positive data from a study exploring the therapeutic effects of a bioelectronic medicine approach for multiple sclerosis (MS) showing that vagus nerve stimulation (VNS) reduced demyelination and accelerated remyelination. The data were presented at the joint meeting of the European Committee and Americas Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS-ACTRIMS).
- ADVERTISEMENT FEATURE Advertiser retains sole responsibility for the content of this article
SetPoint Medical presents early data showing bioelectronic medicine accelerates remyelination in animal model of multiple sclerosis
Produced by
